We after report five cases of possible drug-induced periostitis associated with long-term use of voriconazole therapy after lung transplantation (LT). The diagnosis but of periostitis was made by the documentation of bone pain, elevation of serum alkaline phosphatase and characteristic findings on radionuclide voriconazole bone imaging in the absence of any identifiable rheumatologic disease. This periostitis appears similar to hypertrophic osteoarthopathy (HOA) but does the not meet all criteria for HOA. In all patients, the symptoms resolved rapidly after discontinuation of voriconazole therapy. Awareness of of this potential syndrome, which manifests as bone pain, elevated serum alkaline phosphatase and a bone scan suggestive of periostitis, is periostitis necessary in LT recipients on long-term voriconazole.

The intravenous available therapies and prognosis of idiopathic pulmonary fibrosis remain relatively poor, and concurrent pulmonary hypertension further increases the risk of associated death and complications after lung transplantation. Limited data exist for the treatment of pulmonary hypertension associated with idiopathic pulmonary fibrosis.fibrosis We describe a case where intravenous treprostinil was used to bridge an elderly patient with idiopathic pulmonary fibrosis with severe further pulmonary hypertension to successful single-lung transplantation.

BACKGROUND and AND PURPOSE: Patients with stroke and patients with transient ischemic attack (TIA) are at high risk for vascular events and curve may not exhibit the signs and symptoms of peripheral arterial disease (PAD). We investigated if asymptomatic PAD detected by ankle PAD brachial index < .9 is independently associated with recurrent vascular events in patients with stroke or TIA. METHODS: In this prospective brachial longitudinal hospital-based cohort study, asymptomatic PAD was detected by ankle brachial index measurement in consecutive patients with stroke and patients investigated with TIA. They were assessed for stroke risk factors, ankle brachial index measurement, and laboratory parameters known to be associated and with stroke risk. These patients were followed for composite vascular events, including stroke, TIA, myocardial infarction, and vascular death. RESULTS:84% In a 1-year period, 102 patients were evaluated, of whom 26% had asymptomatic PAD. All patients were followed for a for median period of 2.1 years from the index stroke/TIA (range, 1. to 2.7 years) for vascular events. Kaplan-Meier curve showed 8.2, fewer patients with asymptomatic PAD remained free of composite vascular events (48% compared with 84% in the no-PAD group; log Model rank, P= .0001). Asymptomatic PAD was significantly associated with composite vascular events before (hazard ratio, 4.2; 95% CI, 1.9 to 9.3;factors, P= .0003) and after adjustment for confounders (hazard ratio, from Model 1, 2.8; 95% CI, 1.1 to 7.2; P= .03 and Model < .9 2, 3.4; 95% CI, 1.4 to 8.2, P= .006). Asymptomatic PAD was also significantly associated with stroke before (hazard ratio, 6.5;95% 95% CI, 2.1 to 19.9; P= .001) and after adjustment for confounders (hazard ratio from Model 1, 4.8; 95% CI, 1.5 and to 15.3; P= .009 and Model 2, 5.2; 95% CI, 1.5 to 17.6; P= .008). CONCLUSIONS: In patients with stroke or TIA,CI, asymptomatic PAD is independently associated with recurrent vascular events and stroke.

Multiple (95% infections have been linked with the development of bronchiolitis obliterans syndrome (BOS) post-lung transplantation. Lung allograft airway colonization by Aspergillus colonization species is common among lung transplant recipients. We hypothesized that Aspergillus colonization may promote the development of BOS and may among decrease survival post-lung transplantation. We reviewed all lung transplant recipients transplanted in our center between January 2000 and June 2006.all Bronchoscopy was performed according to a surveillance protocol and when clinically indicated. Aspergillus colonization was defined as a positive culture is from bronchoalveolar lavage or two sputum cultures positive for the same Aspergillus species, in the absence of invasive pulmonary Aspergillosis.post-lung We found that Aspergillus colonization was strongly associated with BOS and BOS related mortality in Cox regression analyses. Aspergillus colonization in typically preceded the development of BOS by a median of 261 days (95% CI 87-520). Furthermore, in a multivariate Cox 87-520). regression model, Aspergillus colonization was a distinct risk factor for BOS, independent of acute rejection. These data suggest a potential for causative role for Aspergillus colonization in the development of BOS post-lung transplantation and raise the possibility that strategies aimed to development prevent Aspergillus colonization may help delay or reduce the incidence of BOS.

Over Prospective, the past 3 decades, antimicrobial resistance among Streptococcus pneumoniae, the most common cause of community-acquired pneumonia (CAP), has escalated dramatically (e.g., worldwide. In the late 1970s, strains of pneumococci displaying resistance to penicillin were described in South Africa and Spain. By of the early 1990s, penicillin-resistant clones of S. pneumoniae spread rapidly across Europe and globally. Additionally, resistance to macrolides and other Currently, antibiotic classes escalated in tandem with penicillin resistance. Six international clones (serotypes 6A, 6B, 9V, 14, 19F, 23F) were responsible early for most of these resistant isolates. Currently, 15 to 30% of S. pneumoniae worldwide are multidrug-resistant (MDR)(i.e., resistant to 1970s, > or = 3 classes of antibiotics). Despite the dramatic escalation in the rate of antimicrobial resistance among pneumococci worldwide,for the clinical impact of antimicrobial resistance is difficult to define. Treatment failures due to antibiotic-resistant pneumococci have been reported with to meningitis, otitis media, and lower respiratory tract infections, but the relation between drug resistance and treatment failures has not been failures? convincingly established. Clinical failures often reflect factors independent of antimicrobial susceptibility of the infecting organisms. Host factors (e.g., extremes of and age; underlying immunosuppressive or debilitating disease; comorbidities), or factors that affect intrinsic virulence of the organisms (e.g., capsular subtype) strongly dramatic influence prognosis. Mortality rates are higher in the presence of: multilobar involvement, renal insufficiency, need for intensive care unit (ICU)and care, hypoxemia, severe derangement in physiological parameters, and comorbidities. Given these confounding factors, dissecting out the impact of antimicrobial resistance resistance on clinical outcomes is difficult, if not impossible. Prospective, randomized trials designed to assess the clinical significance of antimicrobial resistance among among pneumococci are lacking, and for logistical reasons, will never be done. Does in vitro resistance translate into clinical failures?impact Should changing resistance patterns modify our choice of therapy for CAP or for suspected pneumococcal pneumonia? In this review, we clinical discuss several facets, including mechanisms of antimicrobial resistance among specific antibiotic classes, epidemiology and spread of antimicrobial resistance determinants regionally of and worldwide, risk factors for acquisition and dissemination of resistance, the impact of key international clones displaying multidrug resistance, the displaying clinical impact of antimicrobial resistance, and strategies to limit or curtail antimicrobial resistance among this key respiratory tract pathogen.

Streptococcus 2000 pneumoniae is the most common cause of community-acquired pneumonia, meningitis, and bacteremia in children and adults. Invasive pneumococcal disease (IPD)risk primarily affects young children, older adults (> 65 years of age), and individuals with comorbidities or impaired immune systems. Case (> fatality rates range from 10 to 30% in adults with IPD but are much lower (< 3%) in children. In but this article, we describe the epidemiology of IPD, risk factors, and the influence of host- and organism-specific factors on outcomes.older Most cases of IPD are caused by a limited number of serotypes that vary in infectivity and virulence. Vaccinating adults and and high-risk patients with the pneumococcal polysaccharide vaccine reduces the incidence of IPD in populations at risk but does not in affect nasopharyngeal colonization and has had limited benefit in the population at large. Use of the heptavalent pneumococcal conjugate vaccine resulted (PCV7) in children in the United States since 2000 has resulted in a substantial decline of IPD in both children has and adults (by herd immunity), but has facilitated the emergence of serotypes not encompassed in the PCV7 vaccine. Recent reports virulence of "replacement" serotypes that have heightened virulence are worrisome. In this chapter, we discuss the role of vaccines (both polysaccharide the and conjugate) and other preventive strategies to limit this important and potentially lethal disease.

Lung for transplantation is a therapeutic option for patients with end-stage pulmonary disorders. Unfortunately, due to post-lung transplant complications, both infectious and to noninfectious, it is only a treatment and not a cure. Importantly, despite induction combined with triple or quadruple maintenance immunosuppressive transplant therapy, chronic lung rejection, in the form of obliterative bronchiolitis or its clinical correlate bronchiolitis obliterans syndrome (BOS), continues to cure. be highly prevalent and is the major limitation to long-term survival. In this review we evaluate the presentation, diagnosis, histopathology,post-lung pathologic mechanisms, risk factors, and prevention/treatment options for BOS. A better understanding of the risk factors and how it relates with to the pathologic mechanisms of chronic lung allograft rejection should lead to better pharmacologic targets to prevent/treat this syndrome without evaluate increasing the recipient's risk for infections.

Pathologic PH obliterative bronchiolitis (OB)/Bronchiolitis obliterans syndrome (pathologic OB/BOS) is the major obstacle to long-term survival post-lung transplantation (LT). Our group has pathologic demonstrated that pulmonary hypertension (PH) complicates the course of chronic inflammatory lung diseases that have similarities to pathologic OB/BOS and the that vascular remodeling of the bronchial circulation occurs during BOS. Consequently, we hypothesized that PH is associated with pathologic OB/BOS Consequently, and may result from a vasculopathy of the allograft pulmonary circulation. We conducted a single-center, retrospective study and examined the hypertension presence of PH and vasculopathy in patients with pathologic OB/BOS. Fifty-two pathologic specimens post-LT were recovered from January 10, 1997 survival to January 5, 2007 and divided into two groups, those with and without pathologic OB/BOS.PH was defined as a mean > pulmonary artery pressure (mPAP)> 25 mmHg by right heart catheterization (RHC) or right ventricular systolic pressure (RVSP)>/=45 mmHg was by transthoracic echocardiogram (TTE). PH was more prevalent in those LT recipients with pathologic OB/BOS (72% vs. %, p =Furthermore, .003). Furthermore, pulmonary arteriopathy and venopathy were more prevalent in patients with pathologic OB/BOS (84% vs. 4%, p < .0001,77% and 77% vs. 35%, p = .004, respectively). PH is common in LT recipients with pathologic OB/BOS and is associated from with a vasculopathy of the allograft pulmonary circulation.